Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Austria; Department of Internal Medicine, Innsbruck Medical University, Austria.
Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Austria.
Gynecol Oncol. 2013 Jan;128(1):38-43. doi: 10.1016/j.ygyno.2012.09.032. Epub 2012 Oct 9.
Comparative proteomics identified the plasma protein afamin as potential biomarker for ovarian cancer (OC). Significantly decreased afamin plasma concentrations in pre-therapeutic OC patients reconstituted to control values after successful tumor surgery. This study evaluates the association of afamin with survival and response to therapy in serous OC patients within the OVCAD consortium project.
We measured afamin in 215 pre-therapeutic plasma samples, 246 tumor lysates and 109 plasma samples taken 6months after finishing platinum-based chemotherapy. Differences in afamin plasma concentrations among FIGO stages were tested by Kruskal-Wallis test; association of afamin concentrations with overall and progression-free survival was evaluated using Kaplan-Meier survival plots and multivariate adjusted COX regression analysis.
Pre-therapeutic afamin correlated significantly with FIGO stages (p=0.012) and was lower in the presence of metastases (p=0.013) and poorly differentiated OC in patients responding to therapy (p=0.016). Afamin ≥48.0mg/L was also associated with a lower hazard ratio for recurrent disease as compared to afamin <48.0mg/L (p=0.007). Post-therapeutic afamin ≥48mg/L was positively correlated with overall (p<0.001) and progression-free (p=0.012) survival and was lower in non-responders than in responders (p=0.048). Thus, afamin returned post-therapeutically to values of healthy controls in responders (p<0.001) but not in non-responders (p=0.114). Afamin in tumor lysates was lower in poorly differentiated OC than in G 1+2 tumors (p=0.041). Higher afamin concentrations in tumor lysates were associated with increased overall survival (p=0.003).
These data indicate that afamin is associated with therapy response and survival rate in advanced OC patients.
比较蛋白质组学鉴定出血浆蛋白 afamin 是卵巢癌（OC）的潜在生物标志物。在成功进行肿瘤手术后，接受治疗前 OC 患者的 afamin 血浆浓度显著降低至对照值。本研究在 OVCAD 联盟项目中评估了 afamin 与浆液性 OC 患者的生存和对治疗的反应之间的关系。
我们测量了 215 例治疗前血浆样本、246 例肿瘤裂解物和 109 例完成基于铂的化疗后 6 个月的血浆样本中的 afamin。通过 Kruskal-Wallis 检验检验 FIGO 分期之间 afamin 血浆浓度的差异；通过 Kaplan-Meier 生存图和多变量调整 COX 回归分析评估 afamin 浓度与总生存期和无进展生存期的相关性。
治疗前 afamin 与 FIGO 分期显著相关（p=0.012），在存在转移（p=0.013）和治疗反应良好的 OC 患者中，afamin 水平较低（p=0.016）。与 afamin <48.0mg/L 相比，afamin≥48.0mg/L 也与复发病例的风险比降低相关（p=0.007）。治疗后 afamin≥48mg/L 与总生存期（p<0.001）和无进展生存期（p=0.012）呈正相关，在无反应者中低于反应者（p=0.048）。因此，afamin 在反应者中治疗后恢复到健康对照者的水平（p<0.001），但在无反应者中未恢复（p=0.114）。肿瘤裂解物中的 afamin 在低分化 OC 中低于 G1+2 肿瘤（p=0.041）。肿瘤裂解物中较高的 afamin 浓度与总生存期增加相关（p=0.003）。
这些数据表明，afamin 与晚期 OC 患者的治疗反应和生存率相关。
